JPS60252483A - ピリド‐イミダゾリフアマイシンの新規製造法 - Google Patents

ピリド‐イミダゾリフアマイシンの新規製造法

Info

Publication number
JPS60252483A
JPS60252483A JP60102528A JP10252885A JPS60252483A JP S60252483 A JPS60252483 A JP S60252483A JP 60102528 A JP60102528 A JP 60102528A JP 10252885 A JP10252885 A JP 10252885A JP S60252483 A JPS60252483 A JP S60252483A
Authority
JP
Japan
Prior art keywords
formula
alkyl
rifamycin
solvent
molar equivalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60102528A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0469634B2 (enExample
Inventor
ビンセンツオ　カンナタ
ギアン　フランコ　タマグノネ
シルバノ　ピアニ
エギデイオ　マルキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Farmaceutici SpA
Original Assignee
Alfa Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Farmaceutici SpA filed Critical Alfa Farmaceutici SpA
Publication of JPS60252483A publication Critical patent/JPS60252483A/ja
Publication of JPH0469634B2 publication Critical patent/JPH0469634B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP60102528A 1984-05-15 1985-05-14 ピリド‐イミダゾリフアマイシンの新規製造法 Granted JPS60252483A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT3463A/84 1984-05-15
IT03463/84A IT1199374B (it) 1984-05-15 1984-05-15 Processo per la preparazione di pirido-imidazo-rifamicine

Publications (2)

Publication Number Publication Date
JPS60252483A true JPS60252483A (ja) 1985-12-13
JPH0469634B2 JPH0469634B2 (enExample) 1992-11-06

Family

ID=11107845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60102528A Granted JPS60252483A (ja) 1984-05-15 1985-05-14 ピリド‐イミダゾリフアマイシンの新規製造法

Country Status (18)

Country Link
US (1) US4557866A (enExample)
EP (1) EP0161534B1 (enExample)
JP (1) JPS60252483A (enExample)
AR (1) AR241913A1 (enExample)
AT (1) ATE46512T1 (enExample)
AU (1) AU568934B2 (enExample)
CA (1) CA1215708A (enExample)
DE (1) DE3573120D1 (enExample)
DK (1) DK162647C (enExample)
ES (1) ES543115A0 (enExample)
FI (1) FI81101C (enExample)
GR (1) GR851144B (enExample)
IE (1) IE58392B1 (enExample)
IT (1) IT1199374B (enExample)
NO (1) NO164242C (enExample)
PH (1) PH22007A (enExample)
PT (1) PT80446B (enExample)
ZA (1) ZA852971B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509904A (ja) * 2003-11-07 2007-04-19 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2008531623A (ja) * 2005-03-03 2008-08-14 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用
JP2012524060A (ja) * 2009-04-20 2012-10-11 アルファ ワッセルマン ソシエタ ペル アチオニ リファマイシン誘導体
JP2016065058A (ja) * 2006-09-22 2016-04-28 シプラ・リミテッド リファキシミン

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO2003051299A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CA2643364C (en) 2006-03-09 2017-06-06 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
ES2538478T3 (es) 2006-08-02 2015-06-22 Salix Pharmaceuticals, Inc. Métodos para el tratamiento de enteritis por radiación
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG10201607926VA (en) * 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
ES2727728T3 (es) 2008-02-26 2019-10-18 Salix Pharmaceuticals Ltd Métodos para el tratamiento del síndrome del intestino irritable
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
CN101585843B (zh) * 2008-05-21 2011-07-06 重庆赛诺生物药业股份有限公司 一种利福昔明的制备工艺
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2350096B1 (en) 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CA2745980C (en) 2008-12-10 2017-10-31 Cipla Limited Rifaximin complexes
EP2437603A4 (en) 2009-06-02 2012-12-12 Salix Pharmaceuticals Ltd METHODS OF TREATING HEPATIC ENCEPHALOPATHY
CA2773982C (en) 2009-09-13 2018-12-04 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd METHOD FOR THE TREATMENT OF INFECTIONS
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
EP3750526A1 (en) 2010-07-12 2020-12-16 Salix Pharmaceuticals, Inc. Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
AU2012214239B2 (en) 2011-02-11 2016-06-30 Salix Pharmaceuticals, Ltd. Forms of Rifaximin and uses thereof
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2986825T3 (es) 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3140313B1 (en) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
KR102362719B1 (ko) 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN110770244A (zh) * 2017-06-26 2020-02-07 倍尔福股份公司 吡啶并咪唑利福霉素衍生物的抗菌剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509904A (ja) * 2003-11-07 2007-04-19 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2011046738A (ja) * 2003-11-07 2011-03-10 Alfa Wassermann Spa リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2014177500A (ja) * 2003-11-07 2014-09-25 Alfa Wassermann Spa リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2008531623A (ja) * 2005-03-03 2008-08-14 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用
JP2013216710A (ja) * 2005-03-03 2013-10-24 Alfa Wassermann Spa リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用
JP2016065058A (ja) * 2006-09-22 2016-04-28 シプラ・リミテッド リファキシミン
JP2018127470A (ja) * 2006-09-22 2018-08-16 シプラ・リミテッド リファキシミン
JP2020128380A (ja) * 2006-09-22 2020-08-27 シプラ・リミテッド リファキシミン
JP2022003052A (ja) * 2006-09-22 2022-01-11 シプラ・リミテッド リファキシミン
JP2022003038A (ja) * 2006-09-22 2022-01-11 シプラ・リミテッド リファキシミン
JP2023078160A (ja) * 2006-09-22 2023-06-06 シプラ・リミテッド リファキシミン
JP2012524060A (ja) * 2009-04-20 2012-10-11 アルファ ワッセルマン ソシエタ ペル アチオニ リファマイシン誘導体

Also Published As

Publication number Publication date
IT1199374B (it) 1988-12-30
NO164242C (no) 1990-09-12
CA1215708A (en) 1986-12-23
ZA852971B (en) 1985-12-24
FI81101C (fi) 1990-09-10
PH22007A (en) 1988-05-02
IE58392B1 (en) 1993-09-08
GR851144B (enExample) 1985-11-25
AU4251585A (en) 1985-11-21
JPH0469634B2 (enExample) 1992-11-06
ES8603489A1 (es) 1986-01-01
NO851921L (no) 1985-11-18
AU568934B2 (en) 1988-01-14
FI851907L (fi) 1985-11-16
DE3573120D1 (en) 1989-10-26
AR241913A1 (es) 1993-01-29
EP0161534A3 (en) 1987-03-04
ES543115A0 (es) 1986-01-01
FI81101B (fi) 1990-05-31
DK214685A (da) 1985-11-16
DK162647C (da) 1992-04-13
EP0161534B1 (en) 1989-09-20
ATE46512T1 (de) 1989-10-15
PT80446A (en) 1985-06-01
IT8403463A0 (it) 1984-05-15
PT80446B (pt) 1987-11-11
FI851907A0 (fi) 1985-05-14
DK214685D0 (da) 1985-05-14
NO164242B (no) 1990-06-05
DK162647B (da) 1991-11-25
EP0161534A2 (en) 1985-11-21
US4557866A (en) 1985-12-10
IE851191L (en) 1985-11-15

Similar Documents

Publication Publication Date Title
JPS60252483A (ja) ピリド‐イミダゾリフアマイシンの新規製造法
JPS6123192B2 (enExample)
EP0080818B1 (en) Erythromycin b derivatives
US4007169A (en) Method of preparing derivatives of rifamycin S
DE60202483T2 (de) Verfahren zur herstellung von l-ribavirin
US6906184B1 (en) Process for antiparasitic agent
EP0943617B1 (en) Process for the preparation of opiates
CA1218650A (en) Process for the synthesis of pyrido-imidazo- rifamycins
DE68914223T2 (de) Mitomycinderivate.
EP0081305A1 (en) Erythromycin A derivatives
EP1476446B1 (de) Verfahren zur herstellung von n-ethyl-n-(3-(3-cyanopyrazolo-(1,5-a)-pyrimidin-7-yl)phenyl)-acetamid
US20050203287A1 (en) Process for the preparation of sulfamate derivatives
JPH06102656B2 (ja) ラニチジンの製法
KR900004931B1 (ko) 세팔로스포린 화합물의 제조방법
KR960011777B1 (ko) 신규한 결정성 세팔로스포린 유도체 및 그의 제조방법
KR810001154B1 (ko) 5-설파모일-오르트아닐린산의 제조방법
US4042597A (en) Preparation of 2-(2-hydroxy-2-propyl)-1-methyl-5-nitroimidazole
US4567260A (en) Synthesis of 5-deazariboflavine
JPS60169484A (ja) 新規なミニマイシン誘導体
JPH04330045A (ja) デアセチルコルヒチンの製造方法
JPH05163279A (ja) オキサゾピロロキノリンエステルの製造法
MXPA00001315A (en) Improved process for antiparasitic agent
HU183594B (en) Process for producing 11-methoxy-vincamone
JPS6259704B2 (enExample)
JPH0532628A (ja) ピリジルピリドン化合物の製造法

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term